Previous 10 | Next 10 |
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on T...
Pulse Biosciences ( NASDAQ: PLSE ) said that new data on its CellFX System, based on the company' Nano-Pulse Stimulation technology, led to clearance of low-risk basal cell carcinoma lesions . The technology use nonthermal energy to clear lesions with a lower like...
~ Oral video presentation at 2022 American Society for Dermatologic Surgery Annual Conference to highlight high efficacy and favorable cosmesis using NPS technology to clear superficial and nodular basal cell carcinoma (BCC) lesions Pulse Biosciences, Inc . (Nasdaq: PLSE...
The stock market is down again today. Why? Concerns stemming from last week’s Fed meeting and plenty of Fed speak this week have contributed to the latest stock market rout. But that hasn’t been the same when it comes to penny stocks. In this article, we look at a hand full of...
The shares of healthcare equipment maker Pulse Biosciences, Inc. ( NASDAQ: PLSE ) added ~14% pre-market Monday after the company announced that the FDA issued 510(k) clearance for its CellFX System expanding its use to treat the skin condition sebaceous hyperplasia. Th...
Additional 510(k) clearance recently received for use of larger spot size treatment tips with the CellFX System Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS&...
Pulse Biosciences ( NASDAQ: PLSE ) said on Tuesday it had appointed former chief commercial officer, Kevin Danahy, as the Chief Executive Officer, while Chief Executive Officer Darrin Uecker will now serve as Chief Technology Officer. Robert Duggan has been appointed ...
Strategic focus shifting to advance core NPS™ technology in cardiac and oncology sectors, activate additional executive leadership and reduce dermatologic footprint. Former Chief Commercial Officer, Kevin Danahy, appointed Chief Executive Officer; Former Chief Executive...
Pulse Biosciences, Inc. (PLSE) Q2 2022 Earnings Conference Call August 10, 2022 04:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President and Chief Executive Officer Kevin Danahy - Chief Commercial Officer ...
Pulse Biosciences press release ( NASDAQ: PLSE ): Q2 GAAP EPS of -$0.44 misses by $0.04 . Revenue of $0.26M misses by $0.18M . For further details see: Pulse Biosciences GAAP EPS of -$0.44 misses by $0.04, revenue of $0.26M misses by $0.18M
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the fi...
2024-06-25 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...